美康生物
(300439)
| 流通市值：29.99亿 | | | 总市值：39.43亿 |
| 流通股本：2.92亿 | | | 总股本：3.84亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 736,221,523.12 | 374,030,860.65 | 1,742,424,499.51 | 1,406,709,821.37 |
| 营业收入 | 736,221,523.12 | 374,030,860.65 | 1,742,424,499.51 | 1,406,709,821.37 |
| 二、营业总成本 | 706,593,829.78 | 350,212,593.71 | 1,525,930,374.42 | 1,191,514,043.79 |
| 营业成本 | 435,849,307.36 | 225,347,929.5 | 966,144,069.16 | 762,448,197.92 |
| 税金及附加 | 9,213,656.6 | 4,145,273.19 | 15,282,849.54 | 13,184,164.56 |
| 销售费用 | 104,496,129.65 | 52,108,293.45 | 237,206,923.84 | 189,442,033.35 |
| 管理费用 | 86,924,656.62 | 33,660,531.64 | 165,900,996.86 | 118,152,270.43 |
| 研发费用 | 71,451,238.98 | 35,830,195.42 | 146,467,706.46 | 114,751,323.89 |
| 财务费用 | -1,341,159.43 | -879,629.49 | -5,072,171.44 | -6,463,946.36 |
| 其中:利息费用 | 108,446.4 | 377,141.43 | 2,523,612.15 | 1,514,399 |
| 其中:利息收入 | 2,261,671.46 | 1,337,828.91 | 10,351,098.81 | 7,851,136.02 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 226,892.6 | 605,752.74 | 81,517.67 | 380,288.89 |
| 加:投资收益 | 2,342,205.59 | -2,738,528.61 | 14,458,479.33 | 14,474,621.09 |
| 资产处置收益 | 2,981.27 | 10,588.74 | -665,892.86 | 8,580.98 |
| 资产减值损失(新) | -2,404,571.43 | -431,720.71 | -17,776,445.45 | -1,601,744.14 |
| 信用减值损失(新) | -1,303,489.6 | 1,573,699.02 | 20,768,222.16 | 4,900,206.55 |
| 其他收益 | 26,110,145.41 | 11,172,090.16 | 34,170,313.99 | 16,854,995.32 |
| 四、营业利润 | 54,601,857.18 | 34,010,148.28 | 267,530,319.93 | 250,212,726.27 |
| 加:营业外收入 | 3,334,903.38 | 8,137.54 | 21,893,787.72 | 9,159,902.01 |
| 减:营业外支出 | 992,787.6 | 954,470.67 | 7,064,112.18 | 4,392,548.76 |
| 五、利润总额 | 56,943,972.96 | 33,063,815.15 | 282,359,995.47 | 254,980,079.52 |
| 减:所得税费用 | 1,335,896.63 | 3,284,761.12 | 19,685,270.75 | 31,650,540.8 |
| 六、净利润 | 55,608,076.33 | 29,779,054.03 | 262,674,724.72 | 223,329,538.72 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 55,608,076.33 | 29,779,054.03 | 262,674,724.72 | 223,329,538.72 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 56,833,722.63 | 30,397,722.74 | 257,997,230.71 | 224,363,611.78 |
| 少数股东损益 | -1,225,646.3 | -618,668.71 | 4,677,494.01 | -1,034,073.06 |
| 扣除非经常损益后的净利润 | 30,024,575.42 | 20,647,887.87 | 220,406,109.61 | 193,338,584.01 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.15 | 0.08 | 0.67 | 0.58 |
| (二)稀释每股收益 | 0.15 | 0.08 | 0.67 | 0.58 |
| 八、其他综合收益 | 1,302,862.97 | -1,157,261.16 | 10,988,800.8 | -4,248,904.58 |
| 归属于母公司股东的其他综合收益 | 1,063,056.7 | -890,345.17 | 12,198,718.21 | -3,242,176.08 |
| 九、综合收益总额 | 56,910,939.3 | 28,621,792.87 | 273,663,525.52 | 219,080,634.14 |
| 归属于母公司股东的综合收益总额 | 57,896,779.33 | 29,507,377.57 | 270,195,948.92 | 221,121,435.7 |
| 归属于少数股东的综合收益总额 | -985,840.03 | -885,584.7 | 3,467,576.6 | -2,040,801.56 |
| 公告日期 | 2025-08-29 | 2025-04-26 | 2025-04-19 | 2024-10-26 |
| 审计意见(境内) | | | 标准无保留意见 | |